<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p20" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_20{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_20{left:341px;bottom:30px;}
#t3_20{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_20{left:377px;bottom:30px;}
#t5_20{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_20{left:540px;bottom:30px;}
#t7_20{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_20{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_20{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_20{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_20{left:285px;bottom:827px;letter-spacing:-0.25px;}
#tc_20{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_20{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_20{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_20{left:1086px;bottom:28px;letter-spacing:0.2px;}
#tg_20{left:35px;bottom:285px;}
#th_20{left:41px;bottom:279px;letter-spacing:0.12px;word-spacing:-0.07px;}
#ti_20{left:44px;bottom:264px;letter-spacing:0.09px;word-spacing:0.04px;}
#tj_20{left:402px;bottom:264px;letter-spacing:0.11px;}
#tk_20{left:44px;bottom:249px;letter-spacing:0.11px;}
#tl_20{left:44px;bottom:234px;letter-spacing:0.13px;}
#tm_20{left:35px;bottom:224px;}
#tn_20{left:45px;bottom:218px;letter-spacing:0.13px;}
#to_20{left:260px;bottom:218px;}
#tp_20{left:35px;bottom:209px;}
#tq_20{left:41px;bottom:203px;letter-spacing:0.11px;word-spacing:0.01px;}
#tr_20{left:44px;bottom:188px;letter-spacing:0.12px;}
#ts_20{left:44px;bottom:172px;letter-spacing:0.13px;}
#tt_20{left:35px;bottom:163px;}
#tu_20{left:45px;bottom:157px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tv_20{left:331px;bottom:157px;}
#tw_20{left:35px;bottom:148px;}
#tx_20{left:45px;bottom:142px;letter-spacing:0.12px;word-spacing:-0.1px;}
#ty_20{left:555px;bottom:142px;}
#tz_20{left:36px;bottom:760px;letter-spacing:0.48px;}
#t10_20{left:36px;bottom:741px;letter-spacing:0.25px;}
#t11_20{left:115px;bottom:749px;}
#t12_20{left:220px;bottom:760px;letter-spacing:0.32px;word-spacing:-0.31px;}
#t13_20{left:651px;bottom:760px;letter-spacing:0.28px;word-spacing:-0.12px;}
#t14_20{left:1080px;bottom:540px;letter-spacing:-0.09px;}
#t15_20{left:1080px;bottom:521px;letter-spacing:-0.06px;}
#t16_20{left:1080px;bottom:503px;letter-spacing:-0.08px;}
#t17_20{left:1080px;bottom:485px;letter-spacing:-0.09px;}
#t18_20{left:1080px;bottom:466px;letter-spacing:-0.25px;}
#t19_20{left:941px;bottom:629px;letter-spacing:-0.1px;}
#t1a_20{left:941px;bottom:610px;letter-spacing:-0.09px;}
#t1b_20{left:941px;bottom:592px;letter-spacing:-0.08px;}
#t1c_20{left:37px;bottom:513px;letter-spacing:-0.33px;}
#t1d_20{left:37px;bottom:495px;letter-spacing:-0.11px;}
#t1e_20{left:37px;bottom:476px;letter-spacing:-0.33px;word-spacing:-0.05px;}
#t1f_20{left:223px;bottom:683px;letter-spacing:-0.09px;}
#t1g_20{left:223px;bottom:665px;letter-spacing:-0.09px;}
#t1h_20{left:223px;bottom:647px;letter-spacing:-0.08px;}
#t1i_20{left:223px;bottom:628px;letter-spacing:-0.08px;}
#t1j_20{left:223px;bottom:610px;letter-spacing:-0.1px;}
#t1k_20{left:306px;bottom:618px;letter-spacing:-0.09px;}
#t1l_20{left:223px;bottom:551px;letter-spacing:-0.1px;}
#t1m_20{left:223px;bottom:438px;letter-spacing:-0.1px;}
#t1n_20{left:326px;bottom:446px;}
#t1o_20{left:223px;bottom:406px;letter-spacing:-0.1px;}
#t1p_20{left:223px;bottom:374px;letter-spacing:-0.1px;}
#t1q_20{left:223px;bottom:356px;letter-spacing:-0.1px;}
#t1r_20{left:311px;bottom:363px;letter-spacing:-0.13px;}
#t1s_20{left:336px;bottom:356px;letter-spacing:-0.09px;}
#t1t_20{left:223px;bottom:331px;letter-spacing:-0.1px;}
#t1u_20{left:223px;bottom:305px;letter-spacing:-0.08px;}
#t1v_20{left:371px;bottom:589px;letter-spacing:-0.1px;}
#t1w_20{left:371px;bottom:571px;letter-spacing:-0.09px;}
#t1x_20{left:371px;bottom:553px;letter-spacing:-0.09px;}
#t1y_20{left:436px;bottom:560px;letter-spacing:-0.48px;}
#t1z_20{left:502px;bottom:678px;letter-spacing:-0.09px;}
#t20_20{left:502px;bottom:660px;letter-spacing:-0.1px;}
#t21_20{left:580px;bottom:667px;}
#t22_20{left:589px;bottom:660px;}
#t23_20{left:502px;bottom:642px;letter-spacing:-0.1px;}
#t24_20{left:502px;bottom:579px;letter-spacing:-0.08px;}
#t25_20{left:502px;bottom:560px;letter-spacing:-0.11px;}
#t26_20{left:502px;bottom:493px;letter-spacing:-0.08px;}
#t27_20{left:502px;bottom:475px;letter-spacing:-0.09px;}
#t28_20{left:567px;bottom:482px;}
#t29_20{left:670px;bottom:675px;letter-spacing:-0.1px;}
#t2a_20{left:838px;bottom:683px;letter-spacing:-0.11px;}
#t2b_20{left:670px;bottom:657px;letter-spacing:-0.1px;}
#t2c_20{left:670px;bottom:638px;letter-spacing:-0.13px;}
#t2d_20{left:693px;bottom:646px;}
#t2e_20{left:706px;bottom:638px;letter-spacing:-0.1px;}
#t2f_20{left:670px;bottom:606px;letter-spacing:-0.09px;word-spacing:-0.05px;}
#t2g_20{left:670px;bottom:587px;letter-spacing:-0.06px;}
#t2h_20{left:670px;bottom:569px;letter-spacing:-0.18px;word-spacing:-0.09px;}
#t2i_20{left:836px;bottom:576px;letter-spacing:-0.12px;}
#t2j_20{left:670px;bottom:551px;letter-spacing:-0.06px;}
#t2k_20{left:670px;bottom:532px;letter-spacing:-0.13px;}
#t2l_20{left:694px;bottom:540px;}
#t2m_20{left:707px;bottom:532px;letter-spacing:-0.1px;}
#t2n_20{left:670px;bottom:504px;letter-spacing:-0.13px;}
#t2o_20{left:694px;bottom:512px;letter-spacing:-0.12px;}
#t2p_20{left:670px;bottom:486px;letter-spacing:-0.06px;}
#t2q_20{left:670px;bottom:467px;letter-spacing:-0.19px;word-spacing:-0.08px;}
#t2r_20{left:670px;bottom:449px;letter-spacing:-0.13px;}
#t2s_20{left:694px;bottom:457px;letter-spacing:-0.09px;}
#t2t_20{left:718px;bottom:449px;letter-spacing:-0.1px;}
#t2u_20{left:572px;bottom:362px;}
#t2v_20{left:579px;bottom:356px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2w_20{left:581px;bottom:341px;letter-spacing:0.11px;word-spacing:-0.07px;}
#t2x_20{left:581px;bottom:325px;letter-spacing:0.11px;}
#t2y_20{left:793px;bottom:325px;letter-spacing:-0.14px;}
#t2z_20{left:825px;bottom:325px;letter-spacing:0.08px;}
#t30_20{left:572px;bottom:316px;}
#t31_20{left:582px;bottom:310px;letter-spacing:0.12px;}
#t32_20{left:581px;bottom:295px;letter-spacing:0.11px;word-spacing:0.02px;}
#t33_20{left:581px;bottom:279px;letter-spacing:0.1px;word-spacing:0.02px;}
#t34_20{left:581px;bottom:264px;letter-spacing:0.11px;}
#t35_20{left:641px;bottom:264px;letter-spacing:0.13px;}
#t36_20{left:725px;bottom:264px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t37_20{left:581px;bottom:249px;letter-spacing:0.12px;word-spacing:-0.02px;}
#t38_20{left:581px;bottom:234px;letter-spacing:0.12px;}
#t39_20{left:572px;bottom:224px;}
#t3a_20{left:579px;bottom:218px;letter-spacing:0.12px;}
#t3b_20{left:581px;bottom:203px;letter-spacing:0.13px;}
#t3c_20{left:581px;bottom:188px;letter-spacing:0.12px;}
#t3d_20{left:572px;bottom:178px;}
#t3e_20{left:582px;bottom:172px;letter-spacing:0.12px;}
#t3f_20{left:581px;bottom:157px;letter-spacing:0.13px;word-spacing:-0.02px;}
#t3g_20{left:581px;bottom:142px;letter-spacing:0.13px;}
#t3h_20{left:581px;bottom:127px;letter-spacing:0.11px;word-spacing:0.02px;}
#t3i_20{left:581px;bottom:111px;letter-spacing:0.13px;}
#t3j_20{left:371px;bottom:724px;letter-spacing:-0.1px;}
#t3k_20{left:371px;bottom:706px;letter-spacing:-0.09px;}
#t3l_20{left:436px;bottom:713px;letter-spacing:-0.48px;}
#t3m_20{left:36px;bottom:778px;letter-spacing:-0.15px;word-spacing:0.06px;}
#t3n_20{left:671px;bottom:403px;letter-spacing:-0.1px;}
#t3o_20{left:671px;bottom:383px;letter-spacing:-0.09px;}
#t3p_20{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_20{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_20{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_20{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_20{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_20{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_20{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_20{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_20{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_20{font-size:15px;font-family:ArialMT_k0;color:#000;}
.s9_20{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sa_20{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_20{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_20{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_20{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts20" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg20Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg20" style="-webkit-user-select: none;"><object width="1210" height="935" data="20/20.svg" type="image/svg+xml" id="pdf20" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_20" class="t s0_20">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_20" class="t s1_20">® </span>
<span id="t3_20" class="t s0_20">(NCCN </span>
<span id="t4_20" class="t s1_20">® </span>
<span id="t5_20" class="t s0_20">), All rights reserved. NCCN Guidelines </span>
<span id="t6_20" class="t s1_20">® </span>
<span id="t7_20" class="t s0_20">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_20" class="t s2_20">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_20" class="t s2_20">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_20" class="t s3_20">NCCN Guidelines Version 4.2024 </span>
<span id="tb_20" class="t s3_20">Cancer of the Oropharynx (p16 [HPV]-positive) </span>
<span id="tc_20" class="t s4_20">NCCN Guidelines Index </span>
<span id="td_20" class="t s4_20">Table of Contents </span>
<span id="te_20" class="t s4_20">Discussion </span>
<span id="tf_20" class="t s5_20">ORPHPV-2 </span>
<span id="tg_20" class="t s6_20">j </span>
<span id="th_20" class="t s7_20">The clinical staging definitions are based on the AJCC 8th edition for </span>
<span id="ti_20" class="t s7_20">oropharynx cancer (see ST-4 for p16-, and see ST-7 </span><span id="tj_20" class="t s8_20">for p16+). Definitions </span>
<span id="tk_20" class="t s7_20">for nodal staging criteria previously used in clinical trials (AJCC 7th edition) </span>
<span id="tl_20" class="t s7_20">on the management of oropharynx cancer are included. </span>
<span id="tm_20" class="t s6_20">k </span>
<span id="tn_20" class="t s9_20">Principles of Surgery (SURG-A)</span><span id="to_20" class="t s7_20">. </span>
<span id="tp_20" class="t s6_20">l </span>
<span id="tq_20" class="t s7_20">Tumors in the base of tongue, posterior pharyngeal wall, and soft palate </span>
<span id="tr_20" class="t s7_20">require consideration of bilateral neck treatment as do tumors of the tonsil </span>
<span id="ts_20" class="t s7_20">invading the tongue base. </span>
<span id="tt_20" class="t s6_20">n </span>
<span id="tu_20" class="t s9_20">Principles of Radiation Therapy (ORPH-A)</span><span id="tv_20" class="t s7_20">. </span>
<span id="tw_20" class="t s6_20">o </span>
<span id="tx_20" class="t s9_20">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="ty_20" class="t s7_20">. </span>
<span id="tz_20" class="t s5_20">CLINICAL </span>
<span id="t10_20" class="t s5_20">STAGING </span>
<span id="t11_20" class="t sa_20">j </span>
<span id="t12_20" class="t s5_20">TREATMENT OF PRIMARY AND NECK </span><span id="t13_20" class="t s5_20">ADJUVANT TREATMENT </span>
<span id="t14_20" class="t s5_20">Recurrent </span>
<span id="t15_20" class="t s5_20">or </span>
<span id="t16_20" class="t s5_20">persistent </span>
<span id="t17_20" class="t s5_20">disease </span>
<span id="t18_20" class="t sb_20">(ADV-3) </span>
<span id="t19_20" class="t sb_20">Follow-up </span>
<span id="t1a_20" class="t sb_20">(FOLL-A, 1 </span>
<span id="t1b_20" class="t sb_20">of 2) </span>
<span id="t1c_20" class="t s5_20">p16 (HPV)-positive </span>
<span id="t1d_20" class="t s5_20">T0–2,N1 </span>
<span id="t1e_20" class="t sc_20">(single node ≤3 cm) </span>
<span id="t1f_20" class="t s5_20">Resection </span>
<span id="t1g_20" class="t s5_20">of primary and </span>
<span id="t1h_20" class="t s5_20">ipsilateral or </span>
<span id="t1i_20" class="t s5_20">bilateral neck </span>
<span id="t1j_20" class="t s5_20">dissection </span>
<span id="t1k_20" class="t sa_20">k,l </span>
<span id="t1l_20" class="t s5_20">or </span>
<span id="t1m_20" class="t sc_20" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t1n_20" class="t sa_20">n </span>
<span id="t1o_20" class="t s5_20">or </span>
<span id="t1p_20" class="t s5_20">Concurrent systemic </span>
<span id="t1q_20" class="t s5_20">therapy/RT </span>
<span id="t1r_20" class="t sa_20">n,o </span>
<span id="t1s_20" class="t s5_20">(category 2B) </span>
<span id="t1t_20" class="t s5_20">or </span>
<span id="t1u_20" class="t s5_20">Clinical trials </span>
<span id="t1v_20" class="t s5_20">Adverse </span>
<span id="t1w_20" class="t s5_20">pathologic </span>
<span id="t1x_20" class="t s5_20">features </span>
<span id="t1y_20" class="t sa_20">r,s </span>
<span id="t1z_20" class="t s5_20">Extranodal </span>
<span id="t20_20" class="t s5_20">extension </span>
<span id="t21_20" class="t sa_20">t </span>
<span id="t22_20" class="t s5_20">± </span>
<span id="t23_20" class="t s5_20">positive margin </span>
<span id="t24_20" class="t s5_20">Positive </span>
<span id="t25_20" class="t s5_20">margin </span>
<span id="t26_20" class="t s5_20">Other risk </span>
<span id="t27_20" class="t s5_20">features </span>
<span id="t28_20" class="t sa_20">s </span>
<span id="t29_20" class="t s5_20">Systemic therapy/RT </span>
<span id="t2a_20" class="t sa_20">n,o,t </span>
<span id="t2b_20" class="t s5_20">or </span>
<span id="t2c_20" class="t s5_20">RT </span>
<span id="t2d_20" class="t sa_20">n </span>
<span id="t2e_20" class="t s5_20">(category 2B) </span>
<span id="t2f_20" class="t s5_20">Re-resection, if feasible </span>
<span id="t2g_20" class="t s5_20">or </span>
<span id="t2h_20" class="t s5_20">Systemic therapy/RT </span>
<span id="t2i_20" class="t sa_20">n,o </span>
<span id="t2j_20" class="t s5_20">or </span>
<span id="t2k_20" class="t s5_20">RT </span>
<span id="t2l_20" class="t sa_20">n </span>
<span id="t2m_20" class="t s5_20">(category 2B) </span>
<span id="t2n_20" class="t s5_20">RT </span>
<span id="t2o_20" class="t sa_20">n,u </span>
<span id="t2p_20" class="t s5_20">or </span>
<span id="t2q_20" class="t s5_20">Systemic therapy/ </span>
<span id="t2r_20" class="t s5_20">RT </span>
<span id="t2s_20" class="t sa_20">n,o </span>
<span id="t2t_20" class="t s5_20">(category 2B) </span>
<span id="t2u_20" class="t s6_20">r </span>
<span id="t2v_20" class="t s7_20">Pathologic staging criteria differ from clinical staging criteria in HPV-mediated </span>
<span id="t2w_20" class="t s7_20">oropharyngeal cancer. For pathologic stage following resection, see AJCC 8th edition </span>
<span id="t2x_20" class="t s7_20">for appropriate staging criteria (</span><span id="t2y_20" class="t s9_20">ST-7</span><span id="t2z_20" class="t s7_20">). </span>
<span id="t30_20" class="t s6_20">s </span>
<span id="t31_20" class="t s7_20">Adverse pathologic features: extranodal extension, positive margins, close margins </span>
<span id="t32_20" class="t s7_20">(&lt;3 mm), pT3 or pT4 primary, one positive node &gt;3 cm or multiple positive nodes, </span>
<span id="t33_20" class="t s7_20">nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic </span>
<span id="t34_20" class="t s7_20">invasion </span><span id="t35_20" class="t s9_20">(Discussion)</span><span id="t36_20" class="t s7_20">. The definition of an adverse pathologic feature in the context of </span>
<span id="t37_20" class="t s8_20">HPV+ disease is an area of active research. This includes the presence and extent of </span>
<span id="t38_20" class="t s7_20">extranodal extension, and the number of involved nodes. </span>
<span id="t39_20" class="t s6_20">t </span>
<span id="t3a_20" class="t s8_20">The recommendations for patients at high risk with extranodal extension + positive </span>
<span id="t3b_20" class="t s8_20">margins are based on randomized studies involving patients for whom the HPV status </span>
<span id="t3c_20" class="t s7_20">of their tumors was not specified. </span>
<span id="t3d_20" class="t s6_20">u </span>
<span id="t3e_20" class="t s7_20">De-escalation to 50 Gy may be considered in patients with p16 (HPV)-positive </span>
<span id="t3f_20" class="t s7_20">oropharynx cancer who have up to 4 positive lymph nodes, T1–T2 resected to negative </span>
<span id="t3g_20" class="t s7_20">or close margins (&lt;3 mm), and/or N1–N2 disease (excluding bilateral disease based </span>
<span id="t3h_20" class="t s8_20">on ECOG 3311 criteria) with ≤1 mm extranodal extension (Ferris R, et al. J Clin Oncol </span>
<span id="t3i_20" class="t s7_20">2022;40:138-149) (category 2B) </span>
<span id="t3j_20" class="t s5_20">No adverse pathologic </span>
<span id="t3k_20" class="t s5_20">features </span>
<span id="t3l_20" class="t sa_20">r,s </span>
<span id="t3m_20" class="t s5_20">Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate </span>
<span id="t3n_20" class="t sb_20">Post Systemic Therapy/RT or RT </span>
<span id="t3o_20" class="t sb_20">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t3p_20" class="t sd_20">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
